Targeting Phosphatases and Kinases: How to Checkmate Cancer.
cancer stem cell
kinase
phosphatase
phosphatase and kinase inhibitors
targeted therapies
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
04
2021
accepted:
04
10
2021
entrez:
15
11
2021
pubmed:
16
11
2021
medline:
16
11
2021
Statut:
epublish
Résumé
Metastatic disease represents the major cause of death in oncologic patients worldwide. Accumulating evidence have highlighted the relevance of a small population of cancer cells, named cancer stem cells (CSCs), in the resistance to therapies, as well as cancer recurrence and metastasis. Standard anti-cancer treatments are not always conclusively curative, posing an urgent need to discover new targets for an effective therapy. Kinases and phosphatases are implicated in many cellular processes, such as proliferation, differentiation and oncogenic transformation. These proteins are crucial regulators of intracellular signaling pathways mediating multiple cellular activities. Therefore, alterations in kinases and phosphatases functionality is a hallmark of cancer. Notwithstanding the role of kinases and phosphatases in cancer has been widely investigated, their aberrant activation in the compartment of CSCs is nowadays being explored as new potential Achille's heel to strike. Here, we provide a comprehensive overview of the major protein kinases and phosphatases pathways by which CSCs can evade normal physiological constraints on survival, growth, and invasion. Moreover, we discuss the potential of inhibitors of these proteins in counteracting CSCs expansion during cancer development and progression.
Identifiants
pubmed: 34778245
doi: 10.3389/fcell.2021.690306
pmc: PMC8581442
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
690306Informations de copyright
Copyright © 2021 Turdo, D’Accardo, Glaviano, Porcelli, Colarossi, Colarossi, Mare, Faldetta, Modica, Pistone, Bongiorno, Todaro and Stassi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Biol Ther. 2016 May 3;17(5):526-42
pubmed: 26828826
Signal Transduct Target Ther. 2020 Feb 7;5(1):8
pubmed: 32296030
J Natl Cancer Inst. 2016 Sep 15;109(1):
pubmed: 27634934
Cancer Res. 2018 Aug 1;78(15):4191-4202
pubmed: 29880481
Signal Transduct Target Ther. 2020 Apr 15;5(1):36
pubmed: 32296033
Curr Pharm Des. 2012;18(20):2936-45
pubmed: 22571662
Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9435-40
pubmed: 19478061
Nat Rev Cancer. 2009 Mar;9(3):153-66
pubmed: 19238148
Cancer Res. 2010 Nov 1;70(21):8874-85
pubmed: 20959469
Oncotarget. 2014 Sep 30;5(18):8637-50
pubmed: 25226617
Biochem J. 2021 Jul 30;478(14):2899-2920
pubmed: 34319405
Cancers (Basel). 2021 Aug 04;13(16):
pubmed: 34439086
Cell Stem Cell. 2014 Mar 6;14(3):342-56
pubmed: 24607406
Nat Med. 2017 Apr;23(4):472-482
pubmed: 28319094
Oncogene. 2020 Jan;39(5):987-1003
pubmed: 31591478
Cancer Lett. 2018 Jan 1;412:243-255
pubmed: 29050982
Oncotarget. 2016 Aug 23;7(34):54157-54173
pubmed: 27494839
Oncogene. 2013 Jan 10;32(2):209-21
pubmed: 22370645
J Biol Chem. 1996 Nov 1;271(44):27205-8
pubmed: 8910287
Int J Cancer. 2020 Oct 1;147(7):1987-1999
pubmed: 32159851
Nat Rev Cancer. 2006 Apr;6(4):307-20
pubmed: 16557282
Mol Oncol. 2012 Oct;6(5):542-52
pubmed: 22871320
Cell Rep. 2018 May 8;23(6):1651-1664
pubmed: 29742423
Cancer Res. 2017 Aug 15;77(16):4305-4316
pubmed: 28652251
Pharmacol Res. 2021 Mar;165:105463
pubmed: 33513356
FEBS J. 2013 Jan;280(2):489-504
pubmed: 22812510
Life Sci. 2018 Mar 1;196:56-62
pubmed: 29355544
Nucleic Acids Res. 2004 Jan 1;32(Database issue):D153-5
pubmed: 14681382
Annu Rev Biochem. 2011;80:769-95
pubmed: 21548788
Mol Cancer Res. 2019 Jun;17(6):1305-1315
pubmed: 30842251
Cancer Res. 2017 Jun 15;77(12):3268-3279
pubmed: 28400477
Cancer Res. 2008 Nov 1;68(21):8643-53
pubmed: 18974103
Nat Med. 2012 Mar 04;18(4):529-37
pubmed: 22388088
Clin Cancer Res. 2016 Mar 1;22(5):1095-102
pubmed: 26581242
Cancer Cell. 2020 Jul 13;38(1):129-143.e7
pubmed: 32531271
J Neurooncol. 2017 Dec;135(3):487-496
pubmed: 28852935
BMC Cancer. 2019 Jun 24;19(1):618
pubmed: 31234823
Nat Rev Drug Discov. 2015 Feb;14(2):130-46
pubmed: 25633797
Cancer Res. 2007 May 1;67(9):4459-66
pubmed: 17483361
Exp Cell Res. 2013 Dec 10;319(20):3140-9
pubmed: 24012960
Oncogene. 2019 May;38(18):3371-3386
pubmed: 30635656
Cancer Res. 2007 Apr 1;67(7):2922-6
pubmed: 17409395
FEBS Lett. 2012 Aug 14;586(17):2732-9
pubmed: 22626554
Nature. 2014 Jan 23;505(7484):495-501
pubmed: 24390350
Nature. 2001 May 17;411(6835):355-65
pubmed: 11357143
Science. 2000 Mar 24;287(5461):2204-15
pubmed: 10731134
Urol Oncol. 2012 Nov-Dec;30(6):871-8
pubmed: 21396835
Am J Cancer Res. 2020 Oct 01;10(10):3487-3506
pubmed: 33163285
Nat Rev Drug Discov. 2018 Nov 28;17(12):847-849
pubmed: 30482950
Front Endocrinol (Lausanne). 2020 Aug 25;11:566
pubmed: 32982967
Cell Death Dis. 2015 Dec 17;6:e2020
pubmed: 26673665
Acta Pharm Sin B. 2018 Jul;8(4):511-517
pubmed: 30109176
Trends Mol Med. 2008 Apr;14(4):152-60
pubmed: 18329957
Biomed Pharmacother. 2020 May;125:109956
pubmed: 32006900
Crit Rev Oncol Hematol. 2015 Dec;96(3):507-17
pubmed: 26253360
Acta Biochim Biophys Sin (Shanghai). 2018 Apr 1;50(4):355-361
pubmed: 29534162
Sci Rep. 2016 Oct 19;6:35383
pubmed: 27759034
Asian Pac J Cancer Prev. 2019 May 25;20(5):1353-1360
pubmed: 31127889
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
pubmed: 11259830
Pharmacol Res. 2021 Jul;169:105660
pubmed: 33971270
Exp Ther Med. 2011 May;2(3):457-463
pubmed: 22977525
Pharmacol Res. 2018 Sep;135:239-258
pubmed: 30118796
Nat Genet. 1999 Feb;21(2):187-90
pubmed: 9988270
Cell. 2017 Aug 10;170(4):605-635
pubmed: 28802037
Gene. 2002 Feb 20;285(1-2):1-24
pubmed: 12039028
Am J Pathol. 2012 Mar;180(3):1202-1214
pubmed: 22245727
Sci Transl Med. 2019 Jul 17;11(501):
pubmed: 31316003
Cancer Discov. 2018 Jan;8(1):20-23
pubmed: 29311225
Clin Cancer Res. 2017 May 1;23(9):2136-2142
pubmed: 28087641
Nat Rev Cancer. 2017 Jan 27;17(2):93-115
pubmed: 28127048
Cancer Res. 2017 Apr 1;77(7):1763-1774
pubmed: 28202525
Cell Stem Cell. 2020 Oct 1;27(4):590-604.e9
pubmed: 32730753
Cancer Cell. 2004 Sep;6(3):209-14
pubmed: 15380511
Science. 2004 May 21;304(5674):1164-6
pubmed: 15155950
Sci Transl Med. 2018 Feb 7;10(427):
pubmed: 29437150
Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):268-73
pubmed: 19116269
Biomedicines. 2018 Mar 07;6(1):
pubmed: 29518912
Cell Death Dis. 2020 Jun 8;11(6):427
pubmed: 32513919
Science. 1995 Sep 15;269(5230):1575-7
pubmed: 7667636
J Biol Chem. 1995 Apr 14;270(15):8377-80
pubmed: 7721728
Nat Rev Cancer. 2009 Jan;9(1):28-39
pubmed: 19104514
Am J Pathol. 2003 Jun;162(6):1807-15
pubmed: 12759238
Cancers (Basel). 2020 May 31;12(6):
pubmed: 32486505
Nature. 2001 Mar 1;410(6824):37-40
pubmed: 11242034
Clin Transl Oncol. 2006 Mar;8(3):153-60
pubmed: 16648114
Oncogene. 2018 Feb 22;37(8):1107-1118
pubmed: 29155422
Nat Commun. 2015 Dec 03;6:10068
pubmed: 26632666
Methods Mol Biol. 2016;1447:1-23
pubmed: 27514797
Gene. 2016 Feb 15;577(2):101-8
pubmed: 26687711
Cell Death Dis. 2018 Jan 18;9(2):25
pubmed: 29348540
Nat Rev Cancer. 2009 Aug;9(8):537-49
pubmed: 19629069
Tumour Biol. 2010 Dec;31(6):597-604
pubmed: 20614206
Science. 2001 Feb 16;291(5507):1304-51
pubmed: 11181995
Gut. 2021 Jan 12;:
pubmed: 33436496
Hepatology. 2017 May;65(5):1566-1580
pubmed: 28059452
Cell. 2007 Jul 13;130(1):21-4
pubmed: 17632053
J Pharmacol Exp Ther. 2017 Apr;361(1):39-50
pubmed: 28154014
Chem Rev. 2001 Aug;101(8):2511-26
pubmed: 11749386
Int J Cancer. 2019 Aug 15;145(4):1099-1110
pubmed: 30671927
Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9052-7
pubmed: 9256433
Pharmacol Res. 2021 Mar;165:105422
pubmed: 33434619
Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44
pubmed: 25605917
Oncogene. 2015 Jul 23;34(30):3885-94
pubmed: 25263441
Mol Cell. 2017 Jan 19;65(2):347-360
pubmed: 28065597
Oncogene. 2007 May 14;26(22):3100-12
pubmed: 17496909
Trends Mol Med. 2020 Sep;26(9):833-847
pubmed: 32593582
Cold Spring Harb Perspect Biol. 2013 Aug 01;5(8):a009043
pubmed: 23906711
Nature. 2001 Feb 15;409(6822):860-921
pubmed: 11237011
Front Cell Dev Biol. 2019 Feb 18;7:16
pubmed: 30834247
Nat Commun. 2019 May 16;10(1):2197
pubmed: 31097693
Cancers (Basel). 2020 Jun 02;12(6):
pubmed: 32498343
Nat Rev Gastroenterol Hepatol. 2016 Jun;13(6):324-37
pubmed: 27147489
Oncogene. 2017 Jun 22;36(25):3515-3527
pubmed: 28166194
Pharmacol Res. 2018 Jul;133:35-52
pubmed: 29704617
Oncotarget. 2016 Mar 8;7(10):11018-32
pubmed: 26783961
Oncogene. 2014 Feb 20;33(8):939-53
pubmed: 23503460
Thyroid. 2019 May;29(5):674-682
pubmed: 30784360
Nat Rev Mol Cell Biol. 2018 Sep;19(9):547-562
pubmed: 29858604
Nature. 1988 Apr 14;332(6165):644-6
pubmed: 2833705
J Clin Invest. 2011 Jul;121(7):2723-35
pubmed: 21633165
Enzyme Res. 2012;2012:659649
pubmed: 22121480
Biochim Biophys Acta. 2013 Dec;1836(2):211-26
pubmed: 23756181
Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16158-63
pubmed: 17911267
Oncogenesis. 2019 Nov 26;8(12):70
pubmed: 31772161
PLoS One. 2016 Feb 09;11(2):e0148065
pubmed: 26859151
Enzyme Res. 2011;2011:329098
pubmed: 21904669
Exp Cell Res. 2008 Apr 1;314(6):1351-66
pubmed: 18261723
Mol Cell Oncol. 2017 Feb 26;4(3):e1297101
pubmed: 28616575
Adv Cancer Res. 2010;106:53-89
pubmed: 20399956
Nature. 1995 Dec 21-28;378(6559):785-9
pubmed: 8524413